XBIO news

Latest 1 stories · newest Aug 7, 2026

XBIO

Xenetic Biosciences Reports Q2 2026 Financials and Advances DNase Platform

The company reported financial results for the quarter ended June 30, 2026, and highlighted key preclinical data presented at ASCO and a partnership to pursue clinical trials of DNase I.

Earnings Aug 7, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same XBIO feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/XBIO/newsSTART FREE